Market research
EZ1.F Enzon Pharmaceuticals, Inc
F EUR Not available
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 9M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.27
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 9M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.27
About
About Enzon Pharmaceuticals, Inc
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Research context
Enzon Pharmaceuticals, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EZ1.F discussion.
5 years, 7 months ago
Enzon Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 53.6% above its 200 day moving average.
From a valuation standpoint, the stock is 40.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 783.6.
Enzon Pharmaceuticals, Inc's total revenue sank by 30.6% to $34K since the same quarter in the previous year.
Its net income has dropped by 62.6% to $-426K since the same quarter in the previous year.
Finally, its free cash flow fell by 174.0% to $-545K since the same quarter in the previous year.
Based on the above factors, Enzon Pharmaceuticals, Inc gets an overall score of 2/5.